title: The impact of 5-alpha reductase inhibitor vs. alpha-1 adrenergic receptor antagonists on course of prostate premalignant conditions.
abstract: BACKGROUND
  Prostate intraepithelial neoplasm and atypical small acinar proliferation are considered prostate premalignant conditions. Such a diagnosis impacts further follow-up significantly as early detection of prostate cancer is of utmost importance. alpha-1 adrenergic receptor antagonists (i.e. doxazosiunum) and inhibitors of 5-alpha reductase (Finasteride) showed some efficacy in prevention of prostate cancer development.
  
  
  OBJECTIVE
  To assess the impact of both above mentioned drugs on prostate premalignant conditions.
  
  
  METHODS
  From January 2008 till September 2012, 213 patients with one of the above mentioned premalignant condition were retrospectively evaluated. after diagnosis they were assigned to group 1 (n-126)- treated with Finasteride or to group 2 (n-87)-treated with doxazosinum. every 6-7 months rebiopsies were conducted in each patient. Rate of remission and progression was assessed.
  
  
  RESULTS
  In comparison between group 1 and 2 the rate of remission was 35.7% (n-45) vs. 18.4% (n-16) (p = 0.005). In terms of progression, the difference between 1st and 2nd group of patients was 7.1% (n-9) vs. 5.7% (n-5) (p = 0.68).
  
  
  CONCLUSIONS
  Remission of prostate premalignant condition is efficacious with Finasteride and not with doxazosinum. However, in terms of progression there were no differences among both drugs.
authors.affiliation: Urology Department in the Medical and Dentistry Division in Zabrze, Medical University of Silesia in Katowice, Poland.
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Fryczkowski
authors.forename: Piotr
authors.initials: P
authors.lastname: Bryniarski
authors.forename: Maciej
authors.initials: M
authors.lastname: Szczębara
authors.forename: Andrzej
authors.initials: A
authors.lastname: Paradysz
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011230:Precancerous Conditions / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D058891:5-alpha Reductase Inhibitors; D058668:Adrenergic alpha-1 Receptor Antagonists; D018120:Finasteride